

Jason Zhou, Chief Executive Officer, Zymeron Corporation

Jason leads a team of highly motivated scientists and engineers to develop health care innovations in precision therapeutics. He focuses on the company's R&D initiatives in medical countermeasures against chemical, biological and radiological threats. Zymeron's drug pipeline includes pathogen agnostic antimicrobials, chemoprophylactics to prevent hematopoietic acute radiation syndrome, radiotherapy- and chemotherapy-induced myelosuppression, as well as new treatment modalities such as targeted protein degradation for infectious diseases. He supports the business development for the company's rapid diagnostic division. Jason co-founded Zymeron and in his role of chief technology officer 2017-2018 provided strategic guidance to the company's federal funding and contracting units and built an intrapreneurship platform to promote SBIR-funded technology transition and commercialization. He was named CEO of Zymeron in 2018. Previously, he was the Director of Luna nanoWorks Division, Luna Innovations Inc. and the division was later acquired by PE firms to become part of Luna Labs USA. Jason conducted research in the areas of nanomedicine, drug delivery systems, and small molecule drug discovery and development. He has a Ph.D. in chemistry from New York University and a B.S. in chemistry from Peking University.